Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)

Allow physicians not familiar with anti-leukotriene based therapy to test it

Completed

Looking for future studies?

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis Allergic Rhinitis, Allergic Rhinitis, Allergic, Perennial

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis currently on treatment
Voluntary acceptance to participate in the study

Exclusion criteria

Patients with cystic fibrosis
Patients with known hypersensitivity to singulair or any of its components
Patients with severe chronic asthma

Treatment and study plan

MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks

Drug

Primary outcomes

Quality of life measures

Secondary outcomes

Nocturnal wake up, work or school absences, physical activity and recurrence of asthma and/or rhinitis

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

Quality of Life in Asthma and Rhinitis Allergic With Singulair

Important dates

Study start: 2005
Primary completion: 2005
Study completion: 2005
First posted: Sep 26, 2006
Registry last updated: Aug 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed